Compare Medpace Holdings Inc (MEDP) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Meta Platforms Inc — how do they compare? Medpace Holdings Inc trades at $598 (market cap $16.90B), while Meta Platforms Inc trades at $579.18 (market cap $1.53T). The key difference: Meta Platforms Inc is far larger — about 90.5× Medpace Holdings Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | META | |
|---|---|---|
Market Cap | $16.90B | $1.53T |
Sector | Technology | Media |
52-Week High | $620.59 | $790.00 |
52-Week Low | $393.42 | $525.72 |
Enterprise Value | $16.52B | $1.55T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
META trades at $599.12, up 0.71% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations at $10.44 EPS versus $6.70 expected, though Q2 2026 missed estimates. Technical indicators show neutral signals with support at $594 and resistance at $608. The company maintains robust revenue growth, reaching $201B in 2025, while investing heavily in AI infrastructure including the recent Muse Spark launch.
Wall Street remains bullish with 79% buy ratings and $761.95 consensus target, representing 27% upside. Key opportunities include AI monetization potential and strong cash flow generation, while risks involve regulatory lawsuits and elevated capital expenditures. The stock presents a compelling growth story but faces execution risks in competitive AI landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
